CME/CE INFORMATION

HOW TO CLAIM CREDIT

  • Step 1: If you haven't already done so, click “Login” in the upper right corner of this page and enter the email address and password you used to register. If you do not remember your password, follow the link to reset it.
  • Step 2: Select “Evaluations” in the gray menu on the left side of the page.
  • Step 3: Click the blue “Take Evaluation” button to complete the evaluation form. You will need to complete one for each session that you attend. Once completed, click the blue “Print Certificate” button to view/print a PDF of your certificate.


TARGET AUDIENCE

This activity is designed specifically for primary care clinicians, registered nurses, and advanced practice registered nurses who care for patients from rural and underserved areas.


ACCREDITATION

custom image

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RME Collaborative. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 5.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Advances in Management of Difficult-to-Treat Asthma: Overcoming Challenges in Rural and Underserved Settings - 1.00 AMA PRA Category 1 Credit™
  • Improving the Implementation and Adoption of Teledermatology in Rural and Underserved Settings - 1.00 AMA PRA Category 1 Credit™
  • A Vision for the Future: Improving Early Detection and Treatment of Diabetic Retinopathy in Rural and Underserved Settings - 1.00 AMA PRA Category 1 Credit™
  • Ask the Expert: COVID-19 Questions in Primary Care - 0.5 AMA PRA Category 1 Credit™
  • Adolescent and Adult Immunizations: Current Recommendations and Strategies to Reduce Barriers in Rural and Underserved Communities - 1.00 AMA PRA Category 1 Credit™
  • HCV Management in Primary Care: Improving Screening and Treatment in Rural and Underserved Communities - 1.00 AMA PRA Category 1 Credit™

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 5.5 contact hours. Designated for 2.0 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

  • Advances in Management of Difficult-to-Treat Asthma: Overcoming Challenges in Rural and Underserved Settings - 1.00 contact hour; 0.5 pharmacotherapy credit
  • Improving the Implementation and Adoption of Teledermatology in Rural and Underserved Settings - 1.00 contact hour
  • A Vision for the Future: Improving Early Detection and Treatment of Diabetic Retinopathy in Rural and Underserved Settings - 1.00 contact hour; 0.25 pharmacotherapy credit
  • Ask the Expert: COVID-19 Questions in Primary Care - 0.5 contact hour; 0.5 pharmacotherapy credit
  • Adolescent and Adult Immunizations: Current Recommendations and Strategies to Reduce Barriers in Rural and Underserved Communities - 1.00 contact hour; 0.5 pharmacotherapy credit
  • HCV Management in Primary Care: Improving Screening and Treatment in Rural and Underserved Communities - 1.00 contact hour; 0.25 pharmacotherapy credit


SESSION INFORMATION

Welcome and Introductions

Barbara P. Yawn, MD, MSc, MPH (Congress Moderator)
Chief Science Officer, COPD Foundation
Professor of Family and Community Health
University of Minnesota
Minneapolis, MN


Advances in Management of Difficult-to-Treat Asthma: Overcoming Challenges in Rural and Underserved Settings

Meredith C. McCormack, MD, MHS
Associate Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Johns Hopkins University
Baltimore, MD

Learning Objectives

  • Apply evidence‐based strategies to assess and identify asthma patients with suboptimal disease control
  • Develop a personalized treatment plan for patients with asthma based on current guidelines, recommendations, and clinical evidence
  • Identify appropriate therapy for patients with moderate‐to‐severe asthma based on patient preferences, phenotypes, and comorbid conditions
  • Discuss strategies for improving asthma care and management in rural and underserved settings, including self‐management education and asthma action plans


Improving the Implementation and Adoption of Teledermatology in Rural and Underserved Settings

Elizabeth A. Kiracofe, MD
Founder and Principal Dermatologist
Airia Comprehensive Dermatology
Chicago, IL

Learning Objectives

  • Evaluate teledermatology platforms and programs available to rural and underserved communities
  • Discuss the benefits and barriers to implementing teledermatology into clinical practice
  • Implement teledermatology into clinical practice
  • Determine cases and conditions suitable for teledermatology


A Vision for the Future: Improving Early Detection and Treatment of Diabetic Retinopathy in Rural and Underserved Settings

Rishi P. Singh, MD
Staff Surgeon
Cleveland Clinic Cole Eye Institute
Associate Professor of Ophthalmology
Lerner College of Medicine
Case Western Reserve University
Cleveland, OH

Learning Objectives

  • Implement strategies to improve screening for diabetic retinopathy
  • Evaluate recent clinical data on the efficacy and safety of diabetic retinopathy treatments to facilitate management decisions and patient education strategies
  • Discuss strategies, including the use of telemedicine, for improving assessment and management of diabetic retinopathy in rural and underserved areas


Ask the Expert: COVID-19 Questions in Primary Care

Paul E. Sax, MD
Clinical Director, Division of Infectious Diseases
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, MA

Learning Objectives

  • Discuss common questions in primary care related to the treatment and management of COVID-19 in rural and underserved settings
  • Utilize evidence-based strategies to overcome barriers to care in rural and underserved areas during the COVID-19 pandemic


Adolescent and Adult Immunizations: Current Recommendations and Strategies to Reduce Barriers in Rural and Underserved Communities

Paul E. Sax, MD
Clinical Director, Division of Infectious Diseases
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, MA

Learning Objectives

  • Explain the impact of the COVID-19 pandemic on routine vaccination services in rural and underserved settings and current guidance for catch-up vaccination
  • Describe current ACIP recommendations and CDC guidance for adult and adolescent immunizations
  • Utilize evidence-based communication strategies to improve awareness about the importance of routine vaccination and address patient concerns about safe administration


HCV Management in Primary Care: Improving Screening and Treatment in Rural and Underserved Communities

Nancy S. Reau, MD, FAASLD, AGAF
Richard B. Capps Chair of Hepatology
Professor, Department of Internal Medicine
Division of Digestive Diseases and Nutrition
Rush Medical College
Section Chief of Hepatology
Associate Director of Organ Transplantation
Rush University Medical Center
Chicago, IL

Learning Objectives

  • Apply current recommendations for HCV screening to all adults (pregnant and nonpregnant)
  • Utilize effective counseling and follow-up care for patients with a confirmed HCV diagnosis
  • Implement evidence-based guidelines to appropriately treat patients with HCV infection
  • Discuss strategies to overcome barriers to HCV management in rural and underserved settings


DISCLOSURES OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.


FACULTY
Elizabeth A. Kiracofe, MD, has disclosed the following relationships: consultant for Galderma and Regeneron Pharmaceuticals, Inc.; speaker’s bureau for Regeneron Pharmaceuticals, Inc.

Meredith C. McCormack, MD, MHS, has disclosed the following relationships: consultant for Celgene and GlaxoSmithKline; royalties from UpToDate; steering committee for Actelion Pharmaceuticals, Inc.; adjudication committee, clinical trials, for Liquidia Technologies, Inc.; advisory board and chair, Data Safety Monitoring Board, for United Therapeutics.

Nancy S. Reau, MD, FAASLD, AGAF, has disclosed the following relationships: consultant for AbbVie, Inc., Gilead Sciences, Inc., and Intercept Pharmaceuticals, Inc.; grant/research support from Abbott.

Paul E. Sax, MD, has no relevant financial relationships to disclose.

Rishi P. Singh, MD, has disclosed the following relationships: consultant for Alcon, Bausch + Lomb, Genentech, Inc., Novartis Pharmaceuticals, Regeneron Pharmaceuticals, Inc., and ZEISS; grant/research support from Aerie Pharmaceuticals, Inc., Apellis Pharmaceuticals, Inc., and Graybug Vision, Inc.

Barbara P. Yawn, MD, MSc, MPH, has disclosed the following relationships: consultant for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis Pharmaceuticals, and Teva Pharmaceuticals.

PLANNERS AND MANAGERS
The RME Collaborative and PIM planners and managers have nothing to disclose.

ACKNOWLEDGEMENT
These activities are supported by independent medical education grants from AbbVie, Inc.; AstraZeneca; GlaxoSmithKline; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Merck & Co., Inc.; and Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.


DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


CONTACT US
For questions regarding this CME/CE activity, please contact:
RME Collaborative by phone, 800-913-9370 or email, cme@cmeruralhealth.com.

For questions about the accreditation of this activity, please visit www.pimed.com.


DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


MEDIA
Internet activity

COMPUTER SYSTEM REQUIREMENTS

  • System checker: Must meet all requirements of Digitell Live Events Platform
  • Operating system: Windows or Macintosh
  • Supported browsers: HTML5-capable browser – Internet Explorer, Google Chrome, Mozilla Firefox, Safari, Microsoft Edge, Opera
  • Hardware: computer, smartphone, or tablet
  • Broadband Internet connection: high-speed connection preferable

©RME Collaborative, a division of Talem Health, LLC 2020. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.